Transplant coronary heart disease: Challenges and solutions by Jentzer, JC et al.
© 2014 Jentzer et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Transplant Research and Risk Management 2014:6 117–127
Transplant Research and Risk Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
117
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/TRRM.S50846
Transplant coronary heart disease: challenges  
and solutions
Jacob C Jentzer1
Gavin w Hickey1
Sameer J Khandhar2,3
1Heart and vascular institute, 
University of Pittsburgh Medical 
Center, Pittsburgh, PA, USA; 2Perelman 
School of Medicine, University 
of Pennsylvania, Philadelphia, PA, 
USA; 3Heart and vascular institute, 
Penn-Presbyterian Medical Center, 
Philadelphia, PA, USA
Correspondence: Sameer J Khandhar 
Heart and vascular institute,  
Penn-Presbyterian Medical Center, 
4th Floor PHi, 51 North 39th Street, 
Philadelphia, PA 19104, USA 
Tel +1 215 662 9171 
Fax +1 215 243 4637 
email sameer.khandhar@uphs.upenn.edu
Abstract: Cardiac allograft vasculopathy (CAV) remains one of the leading causes of death and 
graft failure after heart transplantation. A variety of causes, including donor heart characteristics, 
recipient risk factors, and immune-mediated influences, are associated with developing CAV. 
In this review, we will focus on the pathophysiology of developing CAV and various methods 
to screen for this condition. The pathogenesis of CAV likely involves repeated injuries to the 
endothelium from a variety of factors such as cellular-mediated rejection, and alloimmune 
factors, including antibody-mediated injury, ischemia-reperfusion injury at time of transplant, 
cytomegalovirus infections, immunosuppression medications, systemic inflammation, and tra-
ditional atherosclerosis risk factors. Patients with significant CAV are often asymptomatic, and 
therefore early detection by routine screening prior to graft dysfunction is crucial. There are a 
variety of invasive, noninvasive, and blood tests that have been studied as screening methods, 
and we will discuss the role of each of these in this review article. Although some treatment 
regimens have been established for CAV, this is an area where further studies and research are 
necessary.
Keywords: cardiac allograft vasculopathy, orthotopic heart transplantation, intra-vascular 
imaging
Introduction
Cardiac allograft vasculopathy (CAV) is widely considered the “Achilles heel” of heart 
transplantation.1 Early posttransplant survival has improved, but median survival 
remains only 10.4 years. CAV is the leading cause of graft failure and the second 
leading cause of death in patients living more than 3 years posttransplant.2 CAV 
is a common clinical problem, occurring in .50% of orthotopic heart transplant 
(OHT) patients by 10 years, with significant associated morbidity and long-term 
mortality.
Although malignancy has become the number one cause of mortality late after 
transplantation, CAV accounts for 10%–14% of deaths beyond the first year after 
transplant.3–6 Death due to CAV typically occurs as the result of graft failure, arrhyth-
mias, or sudden cardiac death.3 Early-onset CAV occurs within the first year after 
OHT and is especially associated with worse long-term outcomes.3,4 Screening 
and diagnosing CAV presents a difficult clinical dilemma. Most patients with CAV 
are asymptomatic because of cardiac sensory denervation, which prevents the 
development of typical angina symptoms. Therefore, there is increasing interest in 
screening patients for subclinical disease, but no consensus on the ideal method 
has been reached. Screening has been performed with conventional tests such as 
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stress testing, coronary angiography, and intravascular 
ultrasound (IVUS), and now by newer methods such as 
optical coherence tomography (OCT), blood tests, and 
coronary computed tomography angiography (CCTA). We 
will focus this review on the pathogenesis (including the 
role of donor-specific antibodies [DSAs]) and diagnosis 
of CAV.
Epidemiology
The prevalence of CAV rises over time and appears to 
increase almost exponentially beyond 5 years, with an 
approximate 10% increase in incidence during each 2-year 
interval after OHT.5 Data from recent International Society 
of Heart and Lung Transplantation (ISHLT) registry estimate 
the prevalence of angiographically detected CAV at 8%–10% 
at 1 year, 20% at 3 years, 30% at 5 years, 45% at 8 years, 
and .50% at 10 years.2,6,7 This contrasts with older estimates 
of CAV rates as high as 40%–50% by 5 years after OHT, 
suggesting delayed and/or declining CAV development with 
modern posttransplant care.8,9 In addition, the true prevalence 
of disease depends on the screening method and definition 
used for CAV. Intravascular imaging with IVUS or OCT has 
been shown to be more sensitive than coronary angiography 
for detecting CAV. At 4–5 years after transplantation, the 
diagnosis of CAV is made in about 55% of patients by IVUS 
or OCT, but only in 33% by angiography.10 On the basis of 
autopsy studies, as many as 75% of transplant patients with 
angiographically normal coronaries had significant intimal 
hyperplasia, although this was not the cause of death in all 
patients.11
CAV can include both coronary artery disease (CAD) 
already present in the donor heart and de novo disease 
that develops in the transplanted heart. It is important 
to differentiate between the two entities, since there is 
increasing utilization of expanded donor hearts because of 
a shortage of available donors, and these may be at higher 
risk for developing CAV.
Risk factors
Risk factors for CAV development include those related 
to the donor, the recipient, and unique transplant-specific 
immune factors.5,12 Major donor-derived risk factors 
for CAV development include increasing donor age 
(especially .40 years), donor history of hypertension, 
male donor, and death from head trauma or explosion.6,7,12,13 
Baseline donor CAD and left ventricular hypertrophy 
appear to increase the risk of significant CAV (especially 
early after OHT).5,14,15
Recipient risk factors for CAV include higher recipient 
body mass index, older age, male recipient, prior ischemic 
heart disease, ventricular assist device support, and recent 
infection.6,7,12 Traditional atherosclerotic risk factors such as 
hypertension, hyperlipidemia (including  triglyceride/high-
density lipoprotein ratio .3), diabetes, and smoking also 
increase the risk of CAV. 3,5,8,16,17
Immune risk factors for CAV include use of 
 Muromonab-CD3 (OKT3) induction, azathioprine (instead 
of  mycophenolate), cyclosporine (instead of tacrolimus), 
acute rejection, development of DSAs, and cytomegalovirus 
(CMV) mismatch (seronegative recipient of a seropositive 
donor organ).6,7,12 CMV infection and increased number 
of acute rejection episodes during the first year after OHT 
significantly increase the risk of CAV, and the effects of 
cellular- and antibody-mediated rejection will be discussed 
later (Table 1).
Pathogenesis
Autopsy studies in transplant recipients with established CAV 
demonstrate that CAV is a combination of intimal fibromus-
cular hyperplasia, traditional atherosclerosis, and vasculitis, 
Table 1 CAv risk factors
Donor-derived factors
 Older donor age or male donor
 Donor CAD
 Donor HTN/LvH
 explosive donor death
Recipient-derived factors (non-modifiable)
 Older recipient age or male recipient
 History of ischemic heart disease
 vAD support prior to OHT
 infection prior to OHT
Recipient metabolic factors (modifiable)
 HTN
 Hyperlipidemia
 insulin resistance
 elevated TG/HDL ratio
 Diabetes
 Smoking
 Higher body mass index
immunologic factors
 Cyclosporine instead of tacrolimus
 Azathioprine instead of mycophenolate
 Recurrent acute cellular rejection
 Antibody-mediated rejection
 CMv infection
 Donor-recipient HLA mismatches
 Circulating anti-HLA antibodies
Abbreviations: CAv, cardiac allograft vasculopathy; CAD, coronary artery 
disease; HTN, hypertension; LvH, left ventricular hypertrophy; vAD, ventricular 
assist device; OHT, orthotopic heart transplant; TG, triglyceride; HDL, high-density 
lipoprotein; CMv, cytomegalovirus; HLA, human leukocyte antigen.
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intimal hyperplasia of the small and large coronary arteries 
being the most common finding.18
Although not completely understood, it is thought 
that the pathogenesis of CAV involves repeated inju-
ries to the endothelium from a variety of factors such as 
 cellular-mediated rejection, alloimmune factors, ischemia-
reperfusion injury at time of transplant, CMV infection, 
immunosuppression medications, systemic inflammation, 
and traditional atherosclerosis risk factors.3,19–21 A schematic 
and theoretical progression of disease is illustrated below. 
Damage to the endothelium leads to smooth muscle cell pro-
liferation, infiltration of the intima with inflammatory cells, 
and collagen deposition.22 This process causes the evolution 
from focal intimal thickening early after transplant to cir-
cumferential diffuse thickening and development of athero-
sclerotic plaques at later stages.23,24 The absolute amount of 
intimal hyperplasia tends to be constant in the entire arterial 
tree but is more noticeable in the distal vasculature given the 
smaller lumen size25 (Figures 1 and 2).
Atherosclerotic coronary lesions already present in 
the donor heart at the time of transplantation can rapidly 
progress after transplantation, leading to focal stenosis that 
usually affects proximal portions of the major epicardial 
coronary arteries.21 The influence of traditional atheroscle-
rotic risk factors such as older donor age, hypertension, 
left ventricular hypertrophy, and donor coronary disease 
emphasizes the overlapping pathophysiology.5–7,21 Early 
CAV, defined as within the first year after heart transplan-
tation, reflects either progression of donor-derived CAD 
(especially focal, proximal lesions) or an aggressive CAV 
phenotype that behaves like an inflammatory vasculitis. 
Although preexisting donor-derived atherosclerosis can 
become clinically significant, whether all such plaques 
will progress is not fully understood. One IVUS-based 
study found that the intimal thickness of donor-derived 
atherosclerotic lesions did not progress faster than other 
segments, nor were they associated with higher mortal-
ity, arguing against progression of donor-derived lesions 
as the dominant cause of CAV.14 This is in contrast to the 
early-onset inflammatory vasculitis-type CAV, which does 
carry a worse prognosis.1
Immunosuppression medications and CMV may both 
directly affect the coronary endothelium. Cyclosporine, 
which is a frequently used immunosuppression agent, may 
directly impair coronary microvascular endothelial function 
when compared with tacrolimus. This, over time, can lead to 
greater intimal thickening.26 CMV infection can also play a 
role in CAV development by direct endothelial cell injury and 
induction of proinflammatory cytokines3,27 (Figure 3).
Role of rejection
Solid organ transplantation induces a cellular reaction 
responsible for acute graft rejection and is a risk factor 
for developing CAV. Rates of cellular rejection are lower 
now with advances in induction and immunosuppressive 
 therapies. However, development of CAV is much more 
complex than simply being due to low levels of chronic cel-
lular rejection. The role of the humoral immune system and 
Typical nontransplant
atherosclerosis
Typical transplant
vascular disease
Variable
Lumen diameter
Lumen location
Remodeling
Adventitial fibrosis
Plaque
Eccentric
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Central
Similar
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Heterogeneous Homogeneous
Figure 1 Differences between classic atherosclerosis and transplant vascular disease or cardiac allograft vasculopathy.
Note: Reprinted from The American Journal of Cardiology, 78(7), Arbustini E, Roberts WC, Morphologic observations in the epicardial coronary arteries and their surroundings 
late after cardiac transplantation (allograft vascular disease), 814–820, Copyright 1996, with permission from Elsevier.76
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intimal smooth muscle cell proliferation and extracellular 
matrix production.20,21 Roughly 9% of patients who undergo 
transplantation are sensitized to HLA antibodies (panel 
 reactive antigen .10%) at the time of the transplant. Clinical 
outcomes in these patients are worse because of increased 
rejection and CAV.2 We now know that even patients with a 
negative cross-match at the time of transplant can develop de 
novo DSAs to HLA and non-HLA antigens after transplanta-
tion, which may play a role in the development of CAV. There 
is no way to predict who will develop these antibodies if they 
are not present at the time of transplant, and it is unknown 
if they trigger the cascade leading to CAV.
With newer Luminex technology (Luminex, Austin, TX, 
USA), determination of the actual DSAs that are present at 
the time of transplant is possible, and studies suggest that 
33% of patients will develop DSAs after OHT.30–33 Luminex 
works by attaching each specific HLA and non-HLA anti-
gens of interest to unique fluorescent microscopic beads, and 
the unique fluorescent emission for each microsphere allows 
for determination of the type of antibodies are  present. These 
de novo antibodies may not be present until several months 
after transplant, perhaps because of greater early immuno-
suppression and the lag time necessary for the development 
of antibodies after antigen exposure. The mere presence 
of DSAs is not necessarily indicative that these antibodies 
are cytotoxic and will damage the endothelium. In order 
to damage the endothelium of the transplanted heart, these 
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Figure 3 Risk factors and pathogenesis of cardiac allograft vasculopathy.
Note: Reproduced from Cardiac allograft vasculopathy: current knowledge and future direction, Colvin-Adams M, Agnihotri A, Clin Transplant, 2011;25(2):175–184. 
Copyright © 2011 John wiley and Sons A/S. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1399-0012.2010.01307.x/abstract.3
Abbreviation: CMv, cytomegalovirus.
Figure 2 Photomicrographs of typical atherosclerosis (A) and cardiac allograft 
vasculopathy with neointimal hyperplasia (B).
Note: Reprinted from The American Journal of Cardiology, 78(7), Arbustini E, Roberts 
wC, Morphologic observations in the epicardial coronary arteries and their 
surroundings late after cardiac transplantation (allograft vascular disease), 814–820, 
Copyright 1996, with permission from elsevier.76
how antibody-mediated injury leads to CAV is just starting 
to be understood and is felt to play a significant role.28,29 Host 
immune response against donor human leukocyte antigen 
(HLA), and non-HLA and endothelial antigens can lead to 
damage to the coronary endothelium of the transplanted 
heart. Donor coronary endothelial injury and endothelial 
dysfunction represent the earliest step in development of 
CAV, provoking an alloimmune inflammatory response 
which leads to an excessive repair process.3,21 This excessive 
repair process causes progressive diffuse luminal narrowing 
involving the entire coronary tree because of circumferential 
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antibodies must activate the complement system. There is 
now a novel Luminex-based assay that detects C1q binding to 
HLA and non-HLA antibodies and thus detects the antibod-
ies that trigger complement activation.34–37 This C1q binding 
DSA by Luminex was recently shown to  predict renal graft 
survival, but the correlation of C1q versus  non-C1q bind-
ing DSA with intimal thickening and CAV is still under 
investigation.37
CAV and rejection can occur even in patients without 
measurable HLA antibodies. Therefore, other antigens 
that can trigger an immune response injury have been 
sought. Other antibodies against antigens such as major 
 histocompatibility-complex class I chain-related anti-
gens A (MICA) have recently been associated in cohorts 
of patients with documented CAV. MICA antigens are 
expressed on endothelial cells, and DSAs to MICA can trig-
ger  complement-dependent injury as well. In a retrospective 
study by Nath et al,38 67% of patients with angiographic 
evidence of CAV had DSAs against HLA or MICA, whereas 
33% of patients without CAV had these DSAs. In a similar 
manner, Zhang et al 39concluded that patients with DSAs 
against HLA or MICA had a 77% survival free of CAV at 
2 years, defined by angiographic stenosis of .50%, com-
pared with 96% in those without these DSAs. However, 
neither study correlated DSA with complement activation, 
endothelial function, or intimal thickening. Although these 
studies suggest an association, they do not answer the ques-
tion of causality.
The role of immune responses to other vascular antigens 
such as vimentin, myosin, and angiotensin II type 1 receptor 
has been linked to antibody-mediated rejection, but their 
role in CAV is even less clear.40 Measuring for antibodies 
against these antigens is more difficult given the lack of 
standardized reagents, and in the future, it may be another 
area of research.
Prospective data on whether DSAs that activate com-
plement are associated with endothelial dysfunction, and 
their relationship with developing intimal thickening is not 
well established, and warrants further studies.
Diagnosis
Patients with significant CAV are often asymptomatic 
and rarely present with angina because of cardiac sensory 
denervation. This makes the diagnosis of CAV difficult 
and routine screening crucial. Manifestations of CAV 
include dyspnea, heart failure, syncope, palpitations, graft 
dysfunction, and even ventricular arrhythmias resulting in 
sudden cardiac death.3 Current guidelines recommend the 
use of routine screening for CAV in asymptomatic OHT 
patients, as well as diagnostic testing for CAV in patients 
with worsening cardiovascular symptoms, arrhythmias, 
or allograft dysfunction.3,5,41,42 Noninvasive testing can be 
performed by stress myocardial perfusion imaging or stress 
 echocardiography. Angiography is the most common method 
of screening; however, its limitation is that it visualizes only 
luminal diameter and cannot measure intimal hyperplasia. 
IVUS and virtual histology-IVUS have advanced our knowl-
edge and detection of CAV by allowing for measurement 
of intima-media thickness and assessment of plaque, but 
are limited by their resolution of 100–300 µm. Therefore, 
other ways to diagnose CAV, such as endothelial function 
testing, OCT imaging, and even computed tomography 
(CT) angiography, are under investigation and now being 
clinically utilized.
There is hope that CAV may be detected through serum 
blood tests such as by biomarkers or DNA and microRNA 
testing. Elevated levels of cardiac troponin, B-type natriuretic 
peptide (BNP), and C-reactive protein (CRP) after OHT 
(particularly if persistent or worsening) are all associated 
with development of CAV as well as graft failure with or 
without adverse cardiac events.1,3 Beyond these traditional 
markers, none are sensitive enough to become part of clini-
cal practice just yet.
Noninvasive testing
The role of noninvasive screening tests for CAV diag-
nosis remains controversial, and each test has important 
limitations.1,3,43 Traditional stress testing is designed to detect 
flow-limiting coronary disease and is likely not effective for 
early detection of CAV because ischemia does not occur 
until there is significant luminal narrowing of at least 70% 
or severe distal disease. The ability to avoid the need for 
invasive testing, nephrotoxic contrast agents, and/or ionizing 
radiation makes their selective use appealing for patients with 
kidney disease or those who remain free from significant CAV 
during late follow-up.3,41,43 Stress testing by either nuclear 
perfusion imaging or dobutamine stress echocardiography 
has good sensitivity (up to 85%–90%) and negative predictive 
value (.95%) for angiographically significant CAV lesions, 
but is far less sensitive for milder preclinical CAV. These tests 
provide prognostic information, since a positive test result 
usually signifies advanced disease.1,3,43,44
Other parameters on stress testing have been studied as 
possible markers for CAV. Systolic dysfunction and wall 
motion abnormalities on resting echocardiography or reduced 
mitral annular systolic tissue Doppler  velocities (s’) #10 cm/s 
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signify significant CAV, but their use is not part of routine 
clinical care.45
CCTA has a sensitivity of up to 89% and an excellent 
negative predictive value of 97% for CAV.46 In a recent 
meta-analysis, the newest-generation CCTA ($$16 slices) 
was compared to coronary angiography and IVUS and the 
analysis showed that CCTA was accurate in excluding CAV 
in the majority of OHT patients, especially when compared to 
standard coronary angiography. When compared to IVUS, the 
sensitivity and negative predictive value of CCTA was lower 
(81% and 50%, respectively), likely because CT is designed 
to assess the lumen size and not intimal  hyperplasia.46 CCTA 
is less invasive than coronary angiography and IVUS, less 
costly, and less resource intensive.47 However, the limitations 
of CCTA include degradation of image quality due to elevated 
resting heart rate (typical for OHT recipients), need for 
nephrotoxic contrast agents, and high doses of ionizing radia-
tion.1,43,48 Despite these, the use of CCTA may be reasonable in 
selected stable OHT patients with preserved renal function as 
a screening tool to exclude significant obstructive CAV.47
At our institution, we prefer dobutamine stress echocar-
diography as an alternative to coronary angiography for 
patients with significant kidney disease (creatinine clearance 
[CrCl] ,30 mL/min or creatinine .2.5 mg/dL), advanced 
age, comorbidities that may limit their survival, and those 
without CAV late after transplant.
invasive testing
Coronary angiography is the standard diagnostic test for CAV 
and is recommended if CAV is suspected. The sensitivity of 
coronary angiography alone for CAV is suboptimal because 
of the diffuse nature of the disease and lack of a normal 
 reference vessel for grading stenosis in many cases.3,5,20 
Despite the lack of sensitivity for early CAV lesions, angiog-
raphy provides important prognostic information and reli-
ably excludes obstructive CAV.3 The International Society 
of Heart Lung Transplantation (ISHLT) has developed a 
nomenclature to help standardize the way CAV is reported 
and compared which has become the preferred classification 
system1 (Figure 4).
The ISHLT CAV grading system incorporates CAV extent 
and severity as well as allograft function to encompass the 
entire spectrum of CAV burden. Angiographic grading systems 
such as that described by Gao et al49 categorize the variable 
angiographic appearance of CAV and are more descriptive in 
nature, but might also help to identify focal CAV lesions that 
are more amenable to revascularization (Figure 5).
Intravascular imaging can be performed by two modali-
ties, and each has certain advantages. IVUS has become 
the standard for the diagnosis of preclinical CAV in view 
of its ability to measure intima and media thickness. The 
IVUS-derived parameters of coronary maximal media-intima 
thickness (MIT), maximal media-intimal area (MIA), mean 
intimal thickness, and atheroma volume offer important 
prognostic information.1,3,5,20,50,51 Rapidly progressive CAV, 
defined by an increase in MIT $0.5 mm and/or an increase 
in MIA $3.5 mm2 between baseline and 1 year, is associated 
with increased rates of death, graft loss, and nonfatal adverse 
cardiac events.41,50,52 In the absence of CAV at 1 year, coronary 
angiography can proceed every 1–2 years until year 3–5, 
after which patients without established CAV may undergo 
less-frequent invasive testing.41
Figure 4 Recommended nomenclature for cardiac allograft vasculopathy.
Note: Reprinted from The Journal of Heart and Lung Transplantation, 29(7), Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung 
Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy–2010, 717–727, Copyright 2010, with permission from elsevier.1
Abbreviations: iSHLT, international Society of Heart and Lung Transplantation; CAv, coronary allograft vasculopathy; LveF, left ventricular ejection fraction.
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Type A lesion
Type B1 lesion
Type B2 lesion
Type C lesion
Figure 5 Anatomic abnormalities in transplant vascular coronary artery disease.
Notes: Type A lesion: discrete, tubular, or multiple stenosis. Type B1 lesion: abrupt 
onset with diffuse distal concentric narrowing and obliterated vessels. Type B2 
lesion: gradual, concentric tapering with distal portion having some residual lumen. 
Type C lesion: narrowed, irregular distal branches with terminations that are often 
nontapered and squared off, ending abruptly. Reprinted from J Am Coll Cardiol. 1988;12, 
Gao SZ, Alderman eL, Schroeder JS, Silverman JF, Hunt SA. Accelerated coronary 
vascular disease in the heart transplant patient: coronary arteriographic findings. 
334–340. Copyright © 1988 with permission from elsevier.49
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Figure 6 OCT imaging of coronary artery of a heart transplant patient with significant intimal hyperplasia and known antibody-mediated rejection (A) and a patient with 
normal-appearing intima without antibodies (B).
Abbreviations: OCT, optimal coherence tomography; DSA, donor-specific antibodies.
Recent studies have evaluated the use of OCT in detecting 
CAV because of its excellent spatial recognition of 10–20 µm, 
which is 10-fold greater than that with IVUS.53 The high 
resolution and the ability to measure the intima and media 
layers individually make this theoretically the ideal screen-
ing tool. The recent OCT CAV study included 15 patients 
without angiographic evidence of CAV and used an intima/
media (I/M) ratio of .1 as a cutoff for diagnosing CAV. In 
this population, 53% had evidence of CAV despite normal 
angiography.25 Additionally, towing to the spatial resolution, 
quantification of atherosclerosis, including lipid-rich and 
calcified plaques, can be performed with OCT. Recently, 
OCT was discovered to have the ability to distinguish newly 
developed CAV from donor-transmitted atherosclerosis, 
potentially allowing for earlier diagnosis of true CAV and 
providing a metric to gauge effectiveness of CAV treatment54 
(Figures 6 and 7).
Many comparisons have been made between these modal-
ities. IVUS technology has been available longer and more 
readily available at catheterization laboratories worldwide. 
With a resolution of 200 µm, IVUS is better suited to detect 
severe disease defined as greater than 500 µm. IVUS also has 
more historical data and certainly provides important prog-
nostic information based on prior longitudinal studies.50,52 
OCT, on the other hand, has a 10-fold higher resolution and 
can measure the intima layer separately from the medial layer, 
detect subtle changes in intimal hyperplasia, and quantify 
atherosclerotic plaques better. Unlike IVUS, OCT does 
require additional contrast administration during coronary 
angiography, which can be problematic in patients with 
kidney disease. Additional OCT-based studies are needed to 
determine the clinical significance of these findings and how 
they correlate with outcomes such as graft survival.
Other invasive measurements of coronary microvascular 
function have been explored to allow for earlier diagnosis 
of CAV, including thrombolysis in myocardial infarction 
(TIMI) frame count and coronary flow reserve.1,3 TIMI frame 
counting is performed by measuring the number of frames 
until contrast dye reaches the end of a vessel during coro-
nary angiography and is increased by microvascular disease. 
Coronary flow reserve utilizes a Doppler wire in the coronary 
artery to measure distal blood flow based on the concept that 
flow is reduced with microvascular disease during hyperemia. 
Several findings on endomyocardial biopsy, including stenotic 
microvasculopathy, endothelialitis, and perivascular fibrosis, 
have been identified as insensitive predictors of CAV.1,20
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Prevention and treatment
Given the risk associated with CAV and limited treatment 
options, prevention of CAV is paramount for optimal OHT 
outcomes.55 Many of the same treatment options for tradi-
tional atherosclerosis have been applied to CAV. Statins are 
the cornerstone of primary CAV prevention by lowering lipid 
levels and attenuating the adverse effects of hyperlipidemia 
on CAV development.3,17,55 In addition, the pleiotropic effects 
of statins may inhibit alloimmune responses, including CMV 
replication. Statins are recommended for all OHT recipients 
regardless of cholesterol levels on the basis of randomized 
trial data showing reduced rates of CAV, all-cause mortal-
ity, and hemodynamically significant rejection with statin 
treatment.3,17,41,55–60 Hypertension control is important for 
CAV prevention, and both angiotensin converting enzyme 
(ACE) inhibitors and calcium-channel blockers appear 
to reduce CAV development and/or progression.3,16,61 As 
with traditional CAD, prevention and control of diabetes 
after OHT likely retards CAV  development. Prevention of 
CMV infection is critical to reducing the risk of developing 
CAV. Universal prophylaxis has been shown to be more 
effective than preemptive therapy for reducing CAV risk 
(Table 2).3,27,62,63
The choice of maintenance immunosuppression regimen 
likely influences CAV risk after transplantation either by 
 preventing rejection or from direct effects of the drugs. The 
combination of tacrolimus and mycophenolate has become 
the most popular combination of routine immunosupres-
sion due to its efficacy at preventing cellular rejection and 
the concept that preventing acute rejeciton will lower the 
risk of CAV.2,5–7,55 The proliferation signal inhibitor (PSI) 
drugs sirolimus and everolimus are potent inhibitors of 
intimal proliferation, and for this reason, they have become 
the drugs of choice for drug-eluting coronary stents to 
prevent in-stent restenosis, a process analogous to CAV 
progression.64
Regimens utilizing a PSI are appealing because the use 
is associated with reduced rates of CAV and improved renal 
function.55,65,66 Current guidelines do not recommend the use 
of PSI for immunosuppression immediately after OHT in 
view of the lack of mortality benefit, fear of higher cellular 
rejection rates, and other adverse effects, including poor 
wound healing.41 Current guidelines suggest adding a PSI to 
ongoing calcineurin inhibitor therapy in place of azathioprine 
or mycophenolate for patients with established CAV.41 There 
are ongoing studies to look at the ideal combination and 
timing of immunosuppression agents, including early use 
of PSI once healing from the transplant surgery is complete. 
Regimens continue to vary between centers, and a consensus 
has not yet been reached.
Other nontraditional agents have been studied as well. 
The combination of antioxidant vitamins C and E reduced 
Intimal thickening
Intimal thickening
Intimal thickening
Intimal thickening Intimal thickening
Lipid
plaque
Lipid
Calcified plaque
Figure 7 Optimal coherence tomography (OCT) imaging of coronary artery in a heart transplant patient showing the ability of OCT to characterize intimal hyperplasia and 
various types of plaques.
Table 2 CAv prevention
Statins
Antihypertensives 
 ACe inhibitors 
 Calcium channel blockers
immunosuppression 
 Tacrolimus (instead of cyclosporine) 
 Mycophenolate (instead of azathrioprine) 
 Sirolimus/everolimus (in higher risk patients)
Cytomegalovirus prophylaxis
Glycemic control
Abbreviations: CAv, cardiac allograft vasculopathy; ACe, angiotensin converting 
enzyme.
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Table 3 CAv treatment options
Statins 
 Goal LDL ,70 mg/dL
Antihypertensives 
 ACe-inhibitors 
 Calcium channel blockers 
 Beta-blockers/nitrates for angina
immunosuppression 
 Sirolimus/everolimus in place of mycophenolate/tacrolimus
Clopidogrel
Antioxidants (vitamin C and E)
Revascularization 
 PCi with drug-eluting stents for amenable lesions 
 CABG in highly selected patients
Re-transplantation for end-stage CAv or ischemic cardiomyopathy
Abbreviations: CAv, cardiac allograft vasculopathy; LDL, low-density lipoprotein; 
ACe, angiotensin converting enzyme; PCi, percutaneous coronary intervention; 
CABG, coronary artery bypass grafting.
CAV progression in a small trial and can be useful when 
modification of the immunosuppression regimen is inap-
propriate or unsuccessful.20,67 Small animal studies using 
aortic allografts have suggested that platelet inhibition with 
clopidogrel might antagonize the development of allograft 
vasculopathy in a manner synergistic with everolimus but 
not cyclosporine, although human data are still lacking.68,69 
The role for traditional antianginal therapy with β-blockers 
and nitrates is limited to symptom management. Patients 
with advanced CAV leading to systolic dysfunction who are 
candidates for retransplantation may benefit from implantable 
cardiac defibrillator placement, since death is often caused 
by ventricular arrhythmias.42,55,70,71
Given the diffuse nature of CAV, revascularization is 
often not feasible, although both surgical and percutaneous 
revascularization can be successful for discrete proximal CAV 
lesions.5,44,55 Percutaneous coronary intervention (PCI) with 
stenting is preferred for patients with focal lesions  amenable 
to this procedure. Restenosis rates are 18% with drug-eluting 
stents and up to 43% with bare-metal stents. These rates 
are higher than in the general population, and therefore, 
drug-eluting stent use is preferable as long as patients can 
tolerate longer-duration dual antiplatelet therapy.5,41,55,64,72 
Long-term survival in patients with CAV amenable to PCI 
is greater than that in those with severe CAV not amenable 
to PCI.73 Fewer OHT recipients with CAV are candidates for 
coronary artery bypass grafting (CABG) than for PCI, but 
the highly-selective CAV patients undergoing CABG may 
have favorable outcomes.5,44,55 CAV is the most common 
indication for retransplantation, which remains the definitive 
therapy when CAV is not amenable to revascularizations 
(Table 3).2,5–7,41,55,74,75
Conclusion
CAV is common after OHT and associated with significant 
morbidity and long-term mortality. Early diagnosis can be 
difficult given the lack of symptoms due to cardiac sensory 
denervation and the diffuse nature of CAV. Given the poor 
prognosis once clinically apparent CAV occurs, a variety 
of screening methods have been investigated. Coronary 
angiography has recently been supplanted by intravascular 
imaging as the gold standard for diagnosing CAV, and fur-
ther studies are necessary to compare IVUS and OCT as the 
imaging tool of choice. Recent advances in medical therapy 
aimed at primary prevention of CAV utilizing statins, CMV 
prophylaxis, and lower cellular rejection rates have resulted 
in a decrease in prevalence of CAV and improvement in 
prognosis. Studies are also ongoing for treatment options 
once CAV develops, including PSI-based immunosuppres-
sion. Although great strides have been made in recent years, 
randomized trials will need to be performed to optimize the 
immunosuppression regimens of OHT patients, especially in 
the first year after transplant, to reduce the prevalence and 
incidence of CAV.
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